A Prospective Cohort Study Assessing the Efficacy and Safety of Tarceva in 2nd Line in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 09 Sep 2015
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PEPITA
- Sponsors Roche
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.
- 14 Oct 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
- 23 Jun 2014 Planned End Date changed from 1 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.